Paolo Prospero Ghia



Professor Paolo Ghia is a Director of the Strategic Program on CLL and Head of the B Cell Neoplasia Research Unit at the San Raffaele Research Hospital. He is also a Full Professor of Medical Oncology at the Vita-Salute San Raffaele University.

As per clinical and research interest, Professor Ghia had dedicated the last 30 years to translational research in onco-hematology and, in particular, in indolent leukemias/lymphomas including chronic lymphocytic leukemia (CLL).

He is a member of international scientific societies, among which:

  • co-chairman of Working Party on lymphoproliferative diseases, GIMEMA (Italian Group of Adult Hematologic Malignancies),
  • member of the international workshop on CLL (iwCLL),
  • member of the Board of the Working Party on lymphoproliferative diseases, GIMEMA (Italian Group of Adult Hematologic Malignancies),
  • President of the European Research Initiative on CLL (ERIC),
  • member of the WHO Clinical Advisory Committee for Lymphocytic and Histiocytic Malignancies,
  • member of the Henry Kunkel Society, New York, USA.


University of Turin
Degree of Doctor of Medicine and Surgery — 1990

University of Turin
Candidate of Sciences in the Field of Human Oncology — 1996

University of Turin, Polo di Orbassano
Specialization in Internal Medicine — 2003

Do you need an appointment?

Contact us and we will take care of you.


Latest publications

Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications.
Haematologica. 2017 Jun;102(6):1085-1090. doi: 10.3324/haematol.2016.157552. PMID: 28255015
Wu SJ, Lin CT, Agathangelidis A, Lin LI, Kuo YY, Tien HF, Ghia P.
Read more
Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia.
Nat Commun. 2017 Jun 9;8:15746. doi: 10.1038/ncomms15746.
Minici C, Gounari M, Übelhart R, Scarfò L, Dühren-von Minden M, Schneider D, Tasdogan A, Alkhatib A, Agathangelidis A, Ntoufa S, Chiorazzi N, Jumaa H, Stamatopoulos K, Ghia P*, Degano M. *Corresponding author and co-senior author.
Read more
Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations.
Haematologica. 2018 Feb 15. pii: haematol.2017.177212. doi: 10.3324/haematol.2017.177212.
Agathangelidis A, Ljungström V, Scarfò L, Fazi C, Gounari M, Pandzic T, Sutton LA, Stamatopoulos K, Tonon G, Rosenquist R, Ghia P.
Read more
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Haematologica. 2018 Apr 19. pii: haematol.2018.189837. doi: 10.3324/haematol.2018.189837. [Epub ahead of print]PMID: 29674504
Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Medina Perez A, Coscia M, Laurenti L, Musuraca G, Farina L, Rivas Delgado A, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bow
Read more
Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments.
Leukemia. 2018 Jun;32(6):1307-1316. doi: 10.1038/s41375-018-0109-x. Epub 2018 Mar 26. PMID: 29700386.
Ghia P, Rawstron A.
Read more
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Haematologica. 2018 Jun 7. pii: haematol.2018.192328. doi: 10.3324/haematol.2018.192328. PMID: 29880603.
Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P.
Read more
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia.
Oncotarget. 2018 May 25;9(40):26019-26031. doi: 10.18632/oncotarget.25419. eCollection 2018 May 25. PMID: 29899839.
Primo D, Scarfò L, Xochelli A, Mattsson M, Ranghetti P, Espinosa AB, Robles A, Gorrochategui J, Martínez-López J, de la Serna J, González M, Gil AC, Anguita E, Iraheta S, Munugalavadla V, Quéva C, Tannheimer S, Rosenquist R, Stamatopoulos K, Ballesteros J, Ghia P.
Read more
High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies.
Blood. 2018 Jul 11. pii: blood-2018-01-826008. doi: 10.1182/blood-2018-01-826008. PMID: 29997221.
Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, Moreno C, Robak T, Stilgenbauer S, Montserrat E.
Read more
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
Am J Hematol. 2018 Aug 20. doi: 10.1002/ajh.25259. PMID: 30129285.
Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P.
Read more
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.
Leukemia. 2019 Jan 3. doi: 10.1038/s41375-018-0335-2. PMID: 30607020
Gounari M, Ntoufa S, Gerousi M, Vilia MG, Moysiadis T, Kotta K, Papakonstantinou N, Scarfò L, Agathangelidis A, Fonte E, Ranghetti P, Nenou A, Xochelli A, Coscia M, Tedeschi A, Stavroyianni N, Muzio M, Stamatopoulos K, Ghia P.
Read more

Do you need an appointment?

Contact us and we will take care of you.